Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects  by Son, Hye-Nam et al.
Biochimica et Biophysica Acta 1833 (2013) 2378–2388
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrMultiple FAS1 domains and the RGD motif of TGFBI act cooperatively to
bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effectsHye-Nam Son a, Ju-Ock Nam b, Soyoun Kim a, In-San Kim a,c,⁎
a Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, Kyungpook National University School of Medicine, Daegu, Republic of Korea
b Department of Ecological Environment Conservation, Kyungpook National University, Sangju-si, Gyeongsangbuk-do, Republic of Korea
c Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea⁎ Corresponding author at: Department of Biochemistry
Research Institute, Kyungpook National University Schoo
Jung-gu, Daegu 700-422, Republic of Korea. Tel.: +82 53 4
E-mail address: iskim@knu.ac.kr (I.-S. Kim).
0167-4889/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbamcr.2013.06.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 22 January 2013
Received in revised form 20 May 2013
Accepted 11 June 2013
Available online 19 June 2013
Keywords:
TGFBI
Angiogenesis
αvβ3 integrin
Anti-tumor effect
FAS1 domainTGFBI, a transforming growth factor β-induced extracellular matrix protein, circulates at a level of ~300 ng/ml in
humans andmodulates several integrin-mediated cellular functions. The protein contains anN-terminal EMI do-
main, four consecutive FAS1 domains, and the RGD motif. Each FAS1 domain and the RGD motif have been
known to interact with avb3 integrin. Here, we found that the binding afﬁnity (Kd) of TGFBI for αvβ3 integrin
was approximately 3.8 × 10−8 M, a value ~2300-fold higher than that of a single FAS1 domain, and demonstrat-
ed that this greater afﬁnitywas due to the cooperative action of the four FAS1 domains and the RGDmotif. More-
over, TGFBI exhibited more potent anti-angiogenic and anti-tumorigenic activities, even at a 100-fold lower
molar dose than the reported effective dose of the FAS1 domain. Finally, our data showed that TGFBI speciﬁcally
targeted the tumor vasculature and accumulated at the tumor site. Collectively, our results support the theory
that TGFBI acts as a potent endogenous anti-tumor and anti-angiogenic molecule by targeting αvβ3 integrin,
and highlights the importance of physiological circulating TGFBI levels in inhibiting tumor growth.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Angiogenesis, the formation of new capillaries from preexisting
blood vessels, is central to tumor growth and metastasis. This process
is a key early event in tumor progression and is essential for the expan-
sion of solid tumors. Thus, targeting the tumor vasculature limits growth
and represents an effective therapy for tumor suppression [1–4].
Endogenous angiogenic inhibitors are molecules that naturally cir-
culate in the body and maintain anti-angiogenic activity, offering a
physiological counterbalance for angiogenic factors [5,6]. Among
many angiogenic factors, integrins represent one of the main targets
of endogenous angiogenic inhibitors. As an example, endostatin and
tumstatin – proteolytic fragments derived from the extracellularmatrix
– interact with the integrin receptors, α5β1 and αvβ3, respectively, on
endothelial cells, leading to alterations in intracellular signaling and
anti-angiogenic effects [7–9]. Thrombospondin-1 (TSP-1), one of the
ﬁrst-identiﬁed endogenous matrix-derived angiogenic inhibitors, ex-
erts anti-angiogenic activity as a full-length gene product. TSP-1 inter-
acts with various molecules, including CD36, CD47, several growth
factors and αvβ3 integrins, and regulates angiogenesis by inhibiting
proliferation and migration and inducing apoptosis of endothelial cells
[10,11].andCell Biology, Cell andMatrix
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l rights reserved.In particular,αvβ3 integrins, which are highly expressed on activat-
ed tumor endothelial cells, are signiﬁcantly involved in the proliferation
and movement of vascular endothelial cells and play critical roles in
tumor angiogenesis and growth [12,13]. Functionally blocking αvβ3
integrins suppresses tumor angiogenesis, supporting the potential im-
portance of these integrins in the angiogenic process [14–17].
TGFBI is a secretory protein induced by transforming growth factor-β
(TGF-β) in a variety of cell types [18–21]. The protein is composed of an
N-terminal cysteine-rich domain (EMI), four consecutive repeats that
share high homology with Drosophila fasciclin-1 (FAS1), and an RGD
motif in the C-terminal region [22]. FAS1 domain- or RGD motif-
containing proteins, including TGFBI, participate in cell adhesion andmi-
gration via interactions with various integrins, including αvβ3 integrin
[23–25]. Several studies have established that the anti-tumorigenic ac-
tivity of TGFBI is markedly downregulated upon hypermethylation of
promoter region of the corresponding gene in various tumor cell lines
[26,27]. Other recent investigations have shown that loss of TGFBI ex-
pression contributes to enhanced cell proliferation in association with
mitotic spindle abnormalities, induction of a tumorigenic phenotype,
and a higher frequency of spontaneous tumors [28,29].
We previously reported that the FAS1 domain of TGFBI exerts
anti-angiogenic activity in vitro and in vivo through direct interactions
with αvβ3 integrin, leading to tumor inhibition [30,31]. However, it is
not known whether the FAS1 domain, a 20-kDa proteolytic fragment
of TGFBI, is generated endogenously; moreover, the effects of the intact,
naturally circulating formof TGFBI on tumor angiogenesis have not been
established. Several studies have shown that the introduction of the
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ﬁnity and speciﬁcity compared with those of RGD monomer [32,33].
TGFBI is composed of multimeric domains – four FAS1 domains and
RGD motif – which interact with αvβ3 integrin. The strong anti-
angiogenic activity and improved therapeutic effect of TGFBI protein
with high afﬁnity and speciﬁcity for αvβ3 integrin can therefore be an-
ticipated. Given that full-length TGFBI containing four FAS1 domains
and one RGD motif circulates at a level of approximately 300 ng/ml in
humans, we hypothesized that regulation of the physiological level of
the protein is sufﬁcient to exert potent anti-tumor growth activity via
inhibition of tumor angiogenesis.
Several endogenous angiogenic inhibitors have been identiﬁed and
subsequently developed as drugs that exhibit sufﬁcient safety and
lower toxicity compared with conventional chemotherapeutic agents.
However, the use of endogenous angiogenic inhibitors has limitations
in human cancer treatment. Therefore, further studies are required to
improve our understanding of the mechanisms underlying the
anti-angiogenic activity of endogenous inhibitors and develop optimal
therapeutic candidates for cancer. In this study, we show that the coop-
erative action of the four FAS1 domains and RGDmotif of TGFBI contrib-
utes to enhanced binding afﬁnity for αvβ3 integrin and inhibitory
effects of tumor angiogenesis and growth.
2. Materials and methods
2.1. Production of recombinant proteins
Recombinant TGFBI protein and forth FAS1 domain, comprising
amino acid residues 68–653 and 498–637 of human TGFBI, were cloned
into pET29b(+) (Novagen; Madison, WI). The deletion mutants of
TGFBI, TGFBI_del. EMI, TGFBI_del. RGD, TGFBI_del. EMI RGD, FAS1_D12,
FAS1_34, and EMI, were cloned into pET29b(+) and translated amino
acid residues 133–653, 16–640, 133–640, 129–377, 368–637, and 16–
105 of human TGFBI, respectively. Each of the recombinant proteins
was induced and puriﬁed as described previously [19,24]. Endotoxin
was removed by phase separation with Triton X-114 [34] and the levels
in the ﬁnal preparations were dropped to below 0.1 EU/ml asmeasured
by Limulus Amebocyte Lysate assay (Sigma-Aldrich).
2.2. Western blot analysis of extracts from various cell lines using
integrin β3 antibody
The cultured cells were lysed in a cell lysis buffer (20 mM Tris,
pH 8.0, 137 mMNaCl, 2 mMEDTA, 1% Triton X-100, a protease inhibitor
cocktail (Sigma) and 10% glycerol) and subjected to SDS-polyacrylamide
gel electrophoresis. The proteins were then transferred to nitrocellulose
membranes (Amersham Pharmacia Biotech, Uppsala, Sweden), which
were blocked for 1 h in TBS-T (50 mM Tris–HCl, 150 mM NaCl, and
0.05% Tween 20) containing 5% non-fat dry milk. The membranes
were then incubated overnight with β3 antibodies (Cell signaling
Technology, Inc.) at 4 °C and washed three times in TBS-T. The proteins
were visualized using an enhanced chemiluminescence reagent (Pierce,
Rockford, IL) and signal detectionwas performedwith an image analyz-
er (LAS-2000, Fuji, Tokyo, Japan).
2.3. In vitro assays for endothelial cell functions related to angiogenesis
In vitro assay was done as described previously [30,35]. HUVECs
(3 × 104 cells/100 μl) were pre-incubated with or without the indicat-
ed concentration of the TGFBI or FAS1 domain for 40 min at 37 °C. For
cell adhesion assay, pre-incubated cells were added to each well of
96-well ELISA plates (Costar, Corning, Inc., NY), which were coated
overnight at 4 °C with 5 μg/ml of vitronectin (R&D Systems) and
blocked for 1 h at room temperature with PBS containing 2% bovine
serum albumin (BSA). After incubation for 5 to 10 min at 37 °C, unat-
tached cells were removed by rinsing with PBS. Attached cells wereincubated for 1 h at 37 °C in 50 mM citrate buffer (pH 5.0) containing
3.75 mM p-nitrophenyl-N-acetyl-beta-D-glucosaminide (hexosamini-
dase substrate) and 0.25% Triton X-100. Enzyme activity was blocked
by adding 50 mM glycine buffer (pH 10.4) containing 5 mM EDTA,
and the absorbance was measured at 405 nM using a Sunrise Basic
microplate reader (Tecan). For cell migration assay, pre-incubated
cells were added to the upper compartment of Transwell plates (8 μM
pore size, Costar, Cambridge,MA), inwhich theundersurface of theﬁlter
membrane was coated with 5 μg/ml of vitronectin for 2 h at room tem-
perature and blocked for 1 h at room temperature with 2% BSA. Cells
were allowed to migrate for 4 h at 37 °C. The ﬁlters were ﬁxed with
4% PFA and stained with crystal violet, and non-migrating cells on the
upper surface of the ﬁlter were removed by wiping with a cotton
swab. The extent of cell migration was determined by light microscopy
and countingwas done in four randomly selected ﬁelds at 200×magni-
ﬁcations. For tube formation assay, pre-incubated cells were seeded on
the surface of Matrigel (Chemicon, International Inc., Temecula, CA),
which was added (100 μl) into each well of a 96-well plate and poly-
merized for 30 min at 37 °C. Cells were incubated for 6 h at 37 °C. The
cells were photographed, and branch points from four random ﬁelds
at 200× magniﬁcations were counted and averaged.
2.4. Antibody production
Anti-human TGFBI monoclonal antibody was produced in BALB/c
mouse by repeated immunizations with recombinant human TGFBI
protein corresponding to amino acids 498–637 produced in E. coli
followed by hybridoma development. A consistently positive hybrid-
oma clone (Clone 18B3) was used to produce ascites ﬂuid, as described
by Harlow and Lane [36]. Ascites ﬂuid was clariﬁed by centrifugation to
remove the lipid layer and the cell pellet and further puriﬁed by Protein
A afﬁnity chromatography (Amersham Biosciences, Uppsala, Sweden)
according to the manufacturer's protocol. The speciﬁcity of the
anti-human TGFBI antibody was tested byWestern blotting and immu-
noprecipitation. This antibody did not cross-react with mouse TGFBI.
2.5. Binding assay
HUVECs were grown to 80% conﬂuence in 96-well plates, washed
twicewith PBS, and incubatedwith elevated concentrations of each pro-
tein for 1 h at room temperature. Cell binding of each protein was
detected by His-probe-HRP antibody (Santa Cruz Biotechnology, Inc.).
In saturation binding assays, αvβ3 integrin or BSA, which was
immobilized on 96-well plates, was incubated with various concentra-
tions of each protein which was diluted in a binding buffer, containing
25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20, 1 mM
MnCl2, 1 mM MgCl2 and 0.1 mM CaCl2, for 2 h at room temperature
and non-bound proteins were removed by washing with PBS. The
total binding of each protein for αvβ3 integrin was detected by
His-probe-HRP antibody and quantiﬁed by measuring horseradish per-
oxidase activity. Enzyme activitywas stopped by adding8 NH2SO4 buff-
er and measured using a Sunrise Basic microplate reader (Tecan) at
490 nM. The afﬁnity of each protein for HUVECs was calculated by
Scatchard analysis. Speciﬁc binding of each protein for αvβ3 integrin
was calculated as the difference between total and nonspeciﬁc binding,
which was measured in every experiment by determining the binding
of each protein to BSA-coated wells. The afﬁnity of each protein for
αvβ3 integrin was calculated using Sigma plot 10.0 software. All data
represent the average of duplicate measurements. All assays were re-
peated at least three times yielding identical results.
2.6. Homology modeling of FAS_D12 and FAS_D34
The homology models of FAS_D12 and D34 were built using the
program SWISS-MODEL (http://swissmodel.expasy.org). The struc-
tures were further reﬁned using the MODELLER program (v9.2)
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were validated by a Ramachandran plot 2.0, indicating no disallowed
conformations (http://dicsoft1.physics.iisc.ernet.in/rp/select.html). The
surface electrostatic potential was calculated using DelPhi calculation
and displayed using Pymol (http://www.pymol.org).
2.7. In vivo tumor assay
Male BALB/c nude mice (5–6 weeks old) were implanted with
1 × 106 B16F10 cells or LLC cells into the ﬂank subcutaneously and
tumor growth and neovascularization after systemic treatment with
exogenous FAS1 domain (5 μM) or TGFBI (50 nM or 10 nM) were
monitored. Experimental groups were i.p. injected every day for 17–
22 days with the indicated concentration of FAS1 domain or TGFBI
in a total volume of 0.1 ml.
2.8. Immunostaining
3 μM parafﬁn sections of B16F10 tumor were incubated with a rat
anti-mouse CD31 antibody (BD Biosciences) at room temperature for
1 h. Subsequently, they were washed with PBS and incubated with
Alexa Fluor 594 conjugated secondary antibody (Invitrogen). Sections
were counterstained with DAPI. Intratumoral microvessel density
was counted at 200× magniﬁcations in a blinded fashion for 4 sepa-
rate ﬁelds and averaged. Each group consisted of six or eight tumor
tissues. Frozen sections (5 μM or 20 μM) of LLC tumors receiving
free Alexa Fluor 488 dye or Alexa Fluor 488 dye labeled TGFBI,
obtained with a cryostat, were dried, ﬁxed with ice-cold acetone,
washed in PBS, then incubated with primary antibodies recognizing
the following epitopes: CD31 and CD61 (BD Biosciences), all at 1:50
dilution. The sections were incubated with the appropriate ﬂuores-
cently conjugated secondary antibody, 1:300 dilution, including
anti-rat Alexa Fluor 488, 594, or 647 conjugated (Invitrogen) antibod-
ies and anti-Armenian hamster IgG Rhodamine conjugated (Abcam)
antibody. Images were acquired using an Olympus BX51 microscope
driven by SPOT Advanced version 4.0.9 imaging software (Diagnostic
Instruments) and a Zeiss Axiovert 200M microscope (Zeiss LSM 5,
Carl Zeiss Inc., Germany). Confocal Z-stack images were created at
1.2 μM intervals throughout the 20 μM of the sections.
2.9. Measurement of half-life of TGFBI in mouse blood
TGFBI was labeled with the green ﬂuorescent dye, FNG-456 (DKC
Corp., Incheon, Korea). After anesthesia, the B16F10 tumor bearing
mouse received a dose of 5 mg/kg of FNG-456 labeled TGFBI in
200 μl of PBS via the mouse tail vein. At time intervals of 2–15 min
after injection, blood was collected from the right ventricle of heart.
The plasma of each mouse was obtained by centrifugation of blood
and the plasma samples were analyzed by ELISA assay. Each experi-
ment consisted of 4 mice. To determine the plasma concentration of
TGFBI, we developed and validated an ELISA using human TGFBI anti-
body (Clone 18B3). The levels of FNG-456 labeled TGFBI were deter-
mined by measuring the emission intensity at 520 nM. The level of
plasma ﬂuorescence was plotted against time and the half-life was
calculated with the PK Functions software.
2.10. Micro-CT angiography
After the LLC tumor bearing mice were euthanized and injected
i.p. with 100 μl of heparin 10 min before tumor sacriﬁce. The thoracic
cavity was opened, an incision was made in the right atrium of the
heart, and a polyethylene cannula (23 G × 3/4″) was passed through
the left ventricle. A 24 ml solution of 0.1 mM sodium nitroprusside in
PBS was perfused at a rate of 6 ml/min to provide a state of maximum
vasodilatation and to remove blood. Mice were then perfused with
24 ml of MICROFIL (MV-122, Carver), a commercially available leadchromate latex, at a rate of 2 ml/min. The infused latex mixture was
allowed to polymerize at room temperature for 1 h before dissection
of tumor tissues. Dissected tumors were immersed in 4% PFA and
then placed in a mixture of water and glycerin. The tumor vasculature
images were acquired from a Skyscan 1076 (Skyscan N.V., Belgium)
X-ray micro-CT system at a voxel resolution of 18 × 18 × 18 μM.
Scanning parameters were set at a voltage of 45 kV, a current of
180 μA, aluminum ﬁlter with 0.5 mm thickness, an exposure time of
590 ms and a rotation step of 0.5°. Three dimensional models of ves-
sel and tissue were reconstructed from acquired cross-section images
by Mimics 13.1 (Materialise NV, Belgium), and their volumes were
measured. The vessel volume divided by the tissue volume was
termed the vessel volume fraction.
2.11. In vivo tumor imaging
TGFBI was labeled to a 4.7:1 incorporated dye:protein ratio with
the near-infrared dye, Cy7.5-NHS (GE Healthcare, UK). Cy7.5-labeled
TGFBI of 100 μl was injected intraperitoneally to LLC tumor bearing
mouse. An equivalent amount of free dye was administered as a con-
trol. Mice were imaged using the eXplore Optix small animal molec-
ular imaging unit (ART Inc., Canada) at 1 and 24 h after conjugate
administration. Analysis of images was performed using eXplore
Optix Analysis Workstation software; a region of interest was manu-
ally selected and the signal intensity was calculated as concentration.
2.12. Statistical analysis
All values are expressed as the means ± SD. The statistical signif-
icance of differences between the experimental and control groups
was evaluated using analysis of variance (ANOVA). A p-value of
b0.05 was considered to be statistically signiﬁcant, and is indicated
by an asterisk over the value.
3. Results
3.1. TGFBI inhibits tumor growth and angiogenesis
We anticipated that the anti-angiogenic activity of TGFBI in vitro
and in vivo would be higher than that of a single FAS1 domain, owing
to the presence of multiple FAS1 domains and RGD motif [30,31]. To
test this hypothesis, we examined the in vitro anti-angiogenic activities
of TGFBI, measuring inhibition of cell adhesion, migration, and tube for-
mation compared with a single FAS1 domain. Vitronectin is a ligand of
theαvβ3 integrin and the ligation between the two induces cellular ad-
hesion and migration to the vitronectin. To determine whether TGFBI
can inhibit vitronectin-induced cell adhesion, we performed a cell ad-
hesion assay using human umbilical vein endothelial cells (HUVECs).
The expression level of αvβ3 integrin on HUVECs was observed by
Western blot (Supplementary Fig. 1A). As shown in Fig. 1A and B,
TGFBI induced a concentration-dependent inhibition of cell adhesion
to vitronectin, with an IC50 (50% inhibitory concentration) value of
105.7 nM, which was 100-fold lower than that observed with the
FAS1 domain alone (9.5 μM). Several types of angiogenic inhibitors
have been reported to display a biphasic, bell-shaped or U-shaped
curve of efﬁcacy [39–41]. We investigated the effect of TGFBI in the
range from 5 nM (340 ng/ml) to 8 μM (544 μg/ml), but no doses of bi-
phasic response were observed on HUVEC adhesion to vitronectin
(Supplementary Fig. 1C). To determine whether these effects of TGFBI
were αvβ3 integrin-dependent, we performed a cell adhesion assay
using HEK293 cell lines stably overexpressing β3 and β5 integrins
(Supplementary Fig. 1B). TGFBI treatment resulted in inhibition of ad-
hesion in β3/HEK293 cells but not in β5/HEK293 cells (Fig. 1C). Analo-
gous to its effects on cell adhesion, TGFBI suppressed endothelial cell
migration towards vitronectin in a concentration-dependent manner.
Moreover, 50 nM TGFBI displayed higher inhibitory activity than
2381H.-N. Son et al. / Biochimica et Biophysica Acta 1833 (2013) 2378–23885 μM FAS1 domain (Fig. 1D, Supplementary Fig. 2A). To determine
whether endothelial cell migration towards vitronectin is suppressed
by treatment of TGFBI, we generated a function blocking antibody
against human TGFBI and examined its effects on endothelial cell mi-
gration. TGFBI inhibited vitronectin-induced HUVEC migration on Boy-
den chambers coated with vitronectin and this inhibition was reversed
by treatment with the functional blockingmonoclonal antibody against
TGFBI (Fig. 1E, Supplementary Fig. 2B). Similar results were obtained in
endothelial tube-formation assays (Fig. 1F, Supplementary Fig. 2C), in
which 50 nM TGFBI showed activity comparable to that of 5 μM FAS1
domain.
We next examined whether the anti-angiogenic effects of TGFBI
in vitro were correlated with in vivo activities using a B16F10 murine
melanoma tumor xenograft model in BALB/c nude mice. Daily0 500 1000 1500 2000
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by the cooperative conformation of FAS1 domains and the RGD
motif.
To characterize the pharmacokinetics of TGFBI, B16F10 tumor
bearing mice were administrated a single bolus intravenous injection
of ﬂuorescence-labeled TGFBI at a dose of 5 mg/kg and serial plasma
samples were subsequently obtained at 2, 15, 30, 45, 60, and 120 min
post-injection. The single dose pharmacokinetic pattern is shown
graphically in Fig. 2D. TGFBI was rapidly removed from the plasma
compartment in mice, exhibiting a terminal half-life of 20.3 min.
3.2. TGFBI binds to HUVECs and αvβ3 integrin with high afﬁnity
Previously, we reported that the FAS1 domain inhibits angiogene-
sis via αvβ3 integrin [31]. To establish whether the more potent
anti-angiogenic activity of TGFBI is due to higher binding afﬁnity to
αvβ3 integrin, we estimated the binding afﬁnity to human umbilical
vein endothelial cells (HUVECs) and αvβ3 integrin. Binding of TGFBI
and FAS1 domain to HUVECs was speciﬁc and hyperbolic. A Scatchard
analysis of the binding curve revealed a single binding site for TGFBI
with a Kd value of 278 nM, compared to a Kd value for the FAS1 do-
main of 26.4 μM. These data indicate that TGFBI binds HUVECs with
100-fold stronger afﬁnity than does the FAS1 domain alone (Fig. 3A,
B).
We further evaluated the binding afﬁnity of TGFBI and FAS1 do-
mains to αvβ3 integrin. Binding of TGFBI was integrin-concentration
dependent (Supplementary Fig. 3) and speciﬁc at the concentrations
ofαvβ3 (4 μg/ml) used for further binding analyses. Enzyme-linked im-
munosorbent assays (ELISAs) showed that TGFBI binding to αvβ3
integrin was concentration-dependent and hyperbolic. The Kd values
for TGFBI and FAS1 domain binding to αvβ3 integrin were 38.2 nM
and 90 μM, respectively (Fig. 3C, D). Interestingly, the binding afﬁnity
of TGFBI for αvβ3 integrin (38.2 nM) was 7.3-fold higher than that for
HUVECs (278 nM), whereas that of FAS1 domain for αvβ3 integrin
(90 μM) was 3.4-fold lower than that for HUVECs (26.4 μM). Our ﬁnd-
ings suggest that the potent anti-angiogenic activity of TGFBI is attribut-
able to its high binding afﬁnity for αvβ3 integrin.
3.3. High afﬁnity TGFBI binding to αvβ3 integrin is mainly attributable to
the four FAS1 domains and RGD motif
To identify the speciﬁc domains of TGFBI involved in αvβ3 integrin
binding, we generated a series of deletion mutants (described in
Fig. 4A). Upon deletion of the RGD motif, the binding afﬁnity of TGFBI
for αvβ3 integrin was decreased by 8.5-fold (from 38 to 325 nM) and
the maximum speciﬁc binding, Bmax, was reduced by half. Deletion of
the EMI domain had only a slight effect on the binding afﬁnity of
TGFBI, suggesting that this region is not critical for interactions with
αvβ3 integrin (Fig. 4B, D). In vitro binding experiments additionally
showed that the EMI domain did not speciﬁcally bind to αvβ3 integrin
(Supplementary Fig. 4). Next, we examined whether binding afﬁnity of
TGFBI for integrin is dependent on the number of FAS1 domains. We
generated constructs incorporating different FAS1 combinations and
numbers, speciﬁcally: FAS1_D1234, FAS1_D12, FAS1_D34, FAS1_D4
and FAS1_D4 [4n] [four repeats of FAS1_D4] (Fig. 4A). All constructs
were capable of interacting with αvβ3 integrin with different afﬁnities
and maximum binding capacities (Fig. 4C, D). FAS1_D1234 protein,
lacking the RGD motif and EMI domain, bound effectively to αvβ3
integrin with an afﬁnity of 340 nM, indicating that the four repeats of
the FAS1 domain coordinate with the RGD motif to achieve strong and
speciﬁc binding to αvβ3 integrin. The number of FAS1 domain repeats
appeared to affect binding afﬁnity since two (FAS1_D12, FAS1_D34) or
four repeats (FAS1_D1234, FAS1_D4 [4n]) of FAS1 domain bound
αvβ3 integrin with higher afﬁnity than the single FAS1 domain,
FAS1_D4. The domain arrangement of FAS1 repeats appeared more crit-
ical for binding, despite the fact that each FAS1 domain sharesconserved sequence motifs. Natural repeats of the FAS1 domains of
TGFBI (FAS1_D1234) showed 12-fold higher afﬁnity than four artiﬁcial-
ly generated repeats of the FAS1 domain (FAS1_D4 [4n]). Furthermore,
upon deletion of FAS1 domains 1 and 2, afﬁnity was decreased by
255-fold to 86.84 μM, whereas deletion of FAS1 domains 3 and 4 only
decreased binding afﬁnity by 2.1-fold to 715 nM, implying that
FAS1_D12 domains play a critical role in binding to αvβ3 integrin. To
explain the differential binding abilities of the FAS1 domain constructs,
in particular, the marked discrepancy between FAS1_D12 and
FAS1_D34, we generated three-dimensional (3D) structural models of
FAS1_D12 and FAS1_D34 based on sequence homology to the crystal
structure of fasciclin (PDB code, 1o70; Fig. 4E). The initial models
were obtained from the Swiss-Prot modeling server and were reﬁned
using the MODELLER program (v9.2; Univ. of San Francisco) [37,38].
The 3D model structures revealed several interesting features. In a sin-
gle FAS1 domain, 18 amino acids centered on conserved YH residues
(YH18) and the C-terminal NKDIL/EPDIM sequence appeared to be crit-
ical for cellular activity via interaction with integrins [24,30,35]. The two
binding motifs identiﬁed, YH18 from FAS1_D1 or FAS1_D3, and NKDIL/
EPDIM sequences from FAS1_D2 or FAS1_D4, are located in close prox-
imity and likely form a critical binding surface for αvβ3 integrin in the
double FAS1 domain constructs, which may explain why the afﬁnity
of double-domain constructs is stronger than that of the single FAS1 do-
main. In addition, the charge distribution of the binding surface of
FAS1_D12 was distinct from that of FAS1_D34. The FAS1_D12 binding
surface, with its exposed acidic and hydrophobic moiety, may form a
more stable complex with αvβ3 integrin than does that of FAS1_D34,
which has a basic moiety and is less hydrophobic.
3.4. TGFBI localizes to the tumor site and inhibits LLC tumor growth
To establish whether TGFBI also suppresses tumor growth in a dif-
ferent tumor model, we transplanted BALB/c nude mice with LLC
tumor cells. TGFBI treatment reduced the growth of LLC tumors in a
similar manner to that observed in the B16F10 xenograft model
(Fig. 5A). TGFBI treatment delayed tumor growth by 5 days compared
with PBS. To further establish the role of TGFBI in tumor angiogenesis,
we examined the vasculature of LLC tumors from mice treated with
TGFBI or PBS using micro-CT (computed tomography), which gener-
ates a comprehensive image of the vasculature of the entire tumor,
thus overcoming the limitations of histologic analyses. A representa-
tive vessel image of the entire tumor mass is shown in Fig. 5B. Consis-
tent with immunohistochemical ﬁndings (Fig. 2B), TGFBI treatment
signiﬁcantly suppressed tumor angiogenesis. In particular, we ob-
served a 6-fold reduction in total vessel volume in TGFBI-treated
mice relative to PBS-treated mice (Fig. 5C). Blood vessel density (vas-
cular volume/tumor volume) was also reduced by 2.2-fold in the
TGFBI-treated group (Fig. 5D). Micro-CT data support the hypothesis
that suppression of tumor growth in TGFBI-treated mice is mainly
due to inhibition of angiogenesis.
To determine the localization of injected TGFBI in vivo, we
performed in vivo optical imaging studies on LLC tumor-bearing mice.
TGFBI labeled with the near-infrared dye Cy7.5 or an equivalent
amount of free dye (control) was injected intraperitoneally into BALB/
c nude mice bearing subcutaneous LLC tumors. Near-infrared optical
images revealed that TGFBI labeled with the Cy7.5 ﬂuorescent signal lo-
calized to the tumor site 1 h after injection with 5-fold greater intensity
than control (Fig. 6A). This localized signal was maintained up to 24 h
after injection. To establish the microscopic localization of TGFBI in tu-
mors, we injected a conjugate of TGFBI with Alexa Fluor 488 dye into
LLC tumor-bearing mice via a single intraperitoneal injection 1 h prior
to sacriﬁce. CD31 immunostaining of tumor tissue slides allowed visu-
alization of the tumor vasculature. Immunostaining for β3 integrin,
conducted to determine the speciﬁc ability of TGFBI to bind αvβ3
integrin, revealed protein localization at the luminal surface of
CD31-positive tumor blood vessels (Fig. 6B). No signal was detected
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Assessment of β3 integrin expression (αvβ3) on LLC tumor tissue
conﬁrmed that the majority of CD31-positive tumor blood vesselsFree proteins v [µM]
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Fig. 5. TGFBI inhibits LLC tumor growth by blocking tumor angiogenesis. (A–D) Male BALB/c nude mice (5–6 weeks old) were implanted with 1 × 106 LLC cells into the ﬂank sub-
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A previous study by our group showed that exogenously adminis-
tered FAS1 domain exerts anti-tumorigenic activity via inhibition of an-
giogenesis through interactions with αvβ3 integrin [31]. In this study,
we further demonstrated that circulating TGFBI containing FAS1 do-
mains functions as a strong endogenous regulator of pathologic angio-
genesis through interactions with αvβ3 integrin. TGFBI exhibited
signiﬁcantly more potent anti-tumorigenic activity than did a single
FAS1 domain. Daily treatment with TGFBI at 340 μg/kg – a 30-fold
lower mass (and a 100-fold lower molar concentration: 50 nM vs.
5 μM) than the 10 mg/kg dose of FAS1 domain alone – led to marked
suppression of tumor growth. Each FAS1 domain of TGFBI bears a
YH18 motif, which is known to interact with αvβ3 integrin and stimu-
late anti-angiogenic activity. However, the YH18 motif and FAS1 do-
main only exhibited anti-angiogenic activity at high concentrations
(up to 100 μM and 5 μM, respectively), indicating that these sequences
are 1000- and 100-fold less active than full-length TGFBI.
The superior anti-angiogenic activity of TGFBI was conﬁrmed by in
vitro cell-adhesion, migration, and tube-formation assays. In particu-
lar, TGFBI strongly suppressed HUVEC migration (up to 60%) at a
1000-fold lower concentration than did the FAS1 domain alone.
Three main characteristics may explain the potent anti-angiogenic
activity of TGFBI. First, TGFBI incorporates multiple (four) FAS1 do-
mains and the RGD motif, which provides efﬁcient binding to αvβ3
integrin. Second, the four FAS1 domain repeats provide not only addi-
tive but also synergistic effects through a domain arrangement thatFig. 4. High afﬁnity of TGFBI binding to αvβ3 integrin is mainly attributed to the four FAS1
proteins. (B, C) Analysis of binding afﬁnity of deletion forms of TGFBI to αvβ3 integrin. Th
various doses of each protein for 2 h at room temperature. Binding of each protein was det
activity. Effects of RGD motif and EMI domain for binding afﬁnity of TGFBI to αvβ3 integr
integrin is shown in C. The afﬁnity of each protein for αvβ3 integrin was calculated from s
of TGFBI and a series of deletion mutants to αvβ3 integrin. Bmax and Kd values of deletion m
tiﬁed by measuring horseradish peroxidase activity (Abs. 490 nM), and expressed as an n-fo
proteins. The homology-based models of FAS1_D12 (left) and FAS1_D34 (right) were calcu
fasciclin (PDB code, 1o70). The critical regions for integrin binding are highlighted on the su
electrostatic potentials displayed on the predicted structures indicated areas of positive (blallows for optimal binding. Third, TGFBI inhibits tumor angiogenesis
via speciﬁc interactions with αvβ3 integrin in vascular endothelial
cells.
Several studies have demonstrated increased speciﬁc binding afﬁn-
ity or activity of proteins with multimeric binding domains compared
with their monomeric counterparts [32]. In this case, TGFBI bound
strongly to HUVECs and αvβ3 integrin, exhibiting 2300-fold higher af-
ﬁnity than the single FAS1 domain. We propose that these properties
of TGFBI reﬂect the combined effects of the four FAS1 domains and
RGD motif on the αvβ3 integrin target. The RGD motif appears to play
a critical role in binding, in view of the ﬁnding that the binding afﬁnity
and capacity (Bmax) of TGFBI were signiﬁcantly decreased upon the de-
letion of this sequence. Although TGFBI consists of multiple αvβ3
integrin binding motifs, the binding reaction possibly involves a simple
1:1 stoichiometry, since its binding graph pattern is speciﬁc and hyper-
bolic. The coordinating interactions of FAS1 domains and the RGDmotif
are supported by our previous ﬁndings that the FAS1 domain competes
with an RGD-containing peptide and inhibits endothelial cell adhesion
and migration in an RGD-dependent manner [24,31].
In fact, RGD-deleted TGFBI constructs (FAS1_D1234) retained con-
siderable binding afﬁnity. We propose that the four FAS1 domain re-
peats confer synergistic effects by virtue of their domain arrangement,
producing optimal binding to αvβ3 integrin. This theory is supported
by two observations: 1) FAS1_D4 [4n], containing four artiﬁcial repeats
of FAS1_D4, displayed 12.3-fold lower afﬁnity than the natural repeat,
FAS1_D1234, but greater binding afﬁnity than the single FAS1_D4 do-
main, indicating that the high binding afﬁnity of the four FAS1 domaindomains and RGD motif. (A) Schematic representation of TGFBI and deletion mutant
e 96-well plate was coated with αvβ3 integrin (4 μg/ml) and then incubated with the
ected by His-probe-HRP antibody and quantiﬁed by measuring horseradish peroxidase
in are shown in B. The number of FAS1 domain-dependent afﬁnity of TGFBI to αvβ3
aturation curves using Sigma plot 10.0 software. (D) The change in Bmax and Kd values
utant proteins to αvβ3 integrin were detected by His-probe-HRP antibody and quan-
ld difference relative to the TGFBI. (E) 3D-structure models of FAS1_D12 and FAS1_D34
lated using Swiss Model Program based on sequence homology of crystal structure of
rface as YH sequences with orange and NKDIL/EPDIM with magenta and green. Surface
ue), neutral (white), and negative (red) regions. The ﬁgure was made by Pymol.
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the individual binding domains. 2) The binding afﬁnities of double
FAS1 domain repeats (FAS1_D12 and FAS1_D34) were enhanced com-
pared with that of the single FAS1 domain.
Although TGFBI is only four times larger than a single FAS1 do-
main, its afﬁnity for αvβ3 integrin is 2300-fold higher. Consequently,
TGFBI exerts anti-angiogenic effects at an approximately 100-fold
lower molar dose than the FAS1 domain, as noted above, supportingTGFBI_Cy7.Free Cy7.5
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tumor vascular endothelial cells. Moreover, several studies have
reported crosstalk between αvβ3 integrin and VEGFR-2, and shown
that inhibition of αvβ3, but not β5, suppresses VEGFR-2 signaling
by VEGF [42]. Therefore, αvβ3 integrin is an attractive therapeutic
target for anti-tumor therapy. Our in vivo and in vitro experiments
showed that TGFBI is strongly bound to vascular endothelial cells ex-
pressing αvβ3 integrins.
Antagonists of αvβ3 integrin, including the humanized monoclonal
antibody, Vitaxin, and the RGDmimetic, Cilengitide, currently undergo-
ing clinical trials, have been reported to extend cancer patient survival
withminimal side effects [43,44]. However, mouse studies by Reynolds
et al. showed that continuous treatment with low concentrations of
RGDmimetics paradoxically stimulates tumor growth and angiogenesis
via enhancement of VEGFR-2 and β3 integrin recycling [39]. Further-
more, the increased VEGF-mediated angiogenesis observed in β3
integrin-deﬁcient mice is caused by a compensatory increase in
VEGFR-2, indicating that β3 integrin is involved in tumor angiogenesis
[45]. In this respect, the local balance between endogenous angiogenic
stimulator and inhibitor levels is critical for tumor angiogenesis, and
thus the physiological blood concentrations of these endogenous angio-
genic inhibitors are of signiﬁcance. Indeed, tumor growth in endostatin
transgenic mice displaying a 1.6-fold increase in circulating endostatin
levels is 3-fold slower than that in control mice. Additionally, in
tumstatin/TSP-1 double-knockout mice, tumor growth is 2-fold faster
compared with that in single tumstatin- or TSP-1-deﬁcient mice [46].
Our results showed that it was possible to inhibit tumor growth by ex-
ogenous administration of TGFBI to redress the imbalance between an-
giogenic stimulator and inhibitor. Consistentwith ourﬁndings, Zhang et
al. reported increased cell proliferation and incidence of spontaneous
tumors upon loss of TGFBI expression in TGFBI−/− mice [29]. And, re-
cent studies using lung and breast cancer cell lines show that TGFBI re-
strains the metastatic potential of these cells, supporting the tumor
suppressor function of TGFBI [47]. However, contrary evidence from
other groups was presented that TGFBI increased the metastatic ability
of colon and ovarian cancer cell lines [48,49]. These opposing effects of
TGFBI suggest the possibility that TGFBI functions to be different,
depending on the cell type and the concentration of TGFBI, and high-
lights the importance of the tumor microenvironment for TGFBI
function.
In fact, the signiﬁcance of the therapeutic concentration of anti-
angiogenic molecules has been reported through various papers. It
shows the biphasic dose–responses, bell-shaped or U-shaped dose–
response, are observed in many other anti-angiogenic molecules in-
cluding RGD-mimetic integrin inhibitors, endostatin and TSP-1
[39–41]. We investigated the effect of TGFBI in the range from 5 nM
(340 ng/ml) to 8 μM (544 μg/ml), which is a 1600-fold higher dose,
but no doses of biphasic responsewere observed in the in vitro assay. Ad-
ditional studies expanding to more types of cell lines and in vivo tumor
models for the biphasic dose–response studies of TGFBI is required.
Previously, TGFBI expression was studied by immunohistochemis-
try in 130 primary human lung carcinomas and 192 cases of breast tu-
mors [50,51]. The results indicated a decrease in TGFBI expression
from benign tissues to carcinomas. However, contrary results were
also reported. Increased concentration of TGFBI was observed in
both serum and urine of the bladder carcinoma patients [52]. Recent-
ly, Chang et al. reported that TGFBI has been conﬁrmed to be
overexpressed in pancreatic cancer tissues, but not the serum levels,
and not statistically correlated with age, gender, histological grade,
and overall tumor stage [53]. These results can be interpreted that a
comparison of the relative expression level with other angiogenic
stimulators is more meaningful than the simple quantiﬁcation of
TGFBI level in tumor microenvironment, offering a physiological
counterbalance for angiogenic stimulators. Therefore, it is necessary
to consider both the tumor cell type and microenvironment when
treating with TGFBI for tumor therapy.In summary, we have demonstrated that circulating TGFBI, a
multi-FAS1 domain protein containing the RGD motif, effectively in-
hibits vascular endothelial cell movement, tumor angiogenesis, and
tumor growth through direct interactions with αvβ3 integrin. Our
data highlight the importance of physiologically circulating TGFBI as
an endogenous anti-angiogenic regulator that inhibits tumor growth.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.06.012.
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